C. R. Bard, Inc. has six divisions that support a broad product offering in the fields of Vascular, Urology, Oncology, and Surgical Specialty. Each division enhances their product offering with comprehensive clinical, educational, and operational programs to help you address the specific challenges of your institution. Click here for more information on programs.
Bard Peripheral Vascular, Inc. provides a range of interventional medical devices specifically designed for the treatment of peripheral arterial, hemodialysis access, and venous disease. These products include the CROSSER™ CTO Catheter, which uses high frequency vibration to facilitate central lumen CTO recanalization; the LIFESTENT® Vascular Stent Systems, the only SFA and proximal popliteal indicated stent; the FLAIR® Endovascular Stent Graft, the only stent graft approved for dialysis access and market leading peripheral PTA balloons such as the VASCUTRAK™ PTA Dilatation Catheter.
Bard Electrophysiology is a global company focused on the development and delivery of a broad range of devices for the diagnosis and treatment of cardiac arrhythmias.
With a history of commitment to quality products and services and many years of experience focusing on electrophysiology, Bard Electrophysiology continues to develop products for users by collaborating with physicians around the world. From diagnostic and therapeutic catheters and accessories to recording systems and cardiac stimulators, Bard Electrophysiology offers a full range of solutions.
Bard Electrophysiology is currently focusing on research and development of catheter-based solutions to aid in the therapy of Atrial Fibrillation, a widely prevalent disorder with few treatment options.
BARD is a global market leader in Urological Diagnostic and Interventional Products providing advanced infection control solutions for patient care.
The Foley Catheter, which BARD introduced over 70 years ago, remains one of the most important products in the urological field. Today, BARD is committed to advancing the technology of diagnosis and intervention to help reduce healthcare costs and improve patient outcomes. One example of our innovative breakthroughs is the BARDEX® I.C. Foley Catheter with BARD® hydrogel and BACTI-GUARD®* silver coating, which is clinically proven to substantially reduce the rate of catheter associated urinary tract infections and reduce the cost of additional therapy and hospital days. Our newest silver-coated device, the AGENTO® I.C. Endotracheal Tube (ETT) has been scientifically proven to reduce ventilator associated pneumonia.
Our STATLOCK® Stabilization Devices replace tape and suture, reducing the incidence of everyday complications associated with vascular access such as dislodgement or unscheduled restarts. Other BARD innovations include the CONTIGEN® BARD Collagen Implant used to treat stress urinary incontinence and the DIGNICARE™ Stool Management System (SMS) which offers advanced features designed for fecal containment.
*Bacti-Guard® silver coating is licensed from Bactiguard AB.
Bacti-Guard is a registered trademark of Bactiguard AB.
Contigen is a registered trademark of Inamed Corporation licensed to C.R. Bard, Inc. or an affiliate.
BARD Oncology Products and Services are designed for the detection, treatment, and management of various cancers. These include specialty access catheters, ports and PICCS; gastroenterological products (endoscopic accessories, percutaneous feeding devices and stents); and biopsy devices.
The FINESSE™ ULTRA Breast Biopsy System provides compassionate control of the patient experience, confident control of sample quality, and efficient control of the biopsy procedure. BARD's HICKMAN® & GROSHONG® catheters have long been the leaders in central venous access.
BARD’s mission to advance the delivery of healthcare is underscored by our acquisition of Dymax Corp. This ultrasound technology allows physicians to have real time visualization of needle placement, reducing the costs associated with multiple needle sticks, reducing vessel damage and improving patient comfort.
Surgical Specialty Products
To complement the BARD Disease State Management focus, BARD maintains a complete line of advanced Surgical Specialty Products and Services that continue to help our customers advance the delivery of health care.
BARD Surgical Specialty Products include prosthetics for soft tissue repair, fixation, and biologic implants, as well as irrigation products for orthopaedic and laparoscopic procedures and topical hemostatic devices.
Two new products that were recently added to the Surgical Specialty Products portfolio include:
- The XENMATRIX® graft has a unique open structure that encourages tissue integration for hernia and abdominal wall repair. Proprietary manufacturing techniques minimize processing in order to preserve both the strength and structure of the graft. This method results in an open scaffold that allows for early population of host cells, collagen, and blood vessel formation.
- The SORBAFIX™ Absorbable Fixation System is unique from its design, to its delivery, to its easy-to-see color. It is indicated for prosthetic mesh fixation and the approximation of soft tissue in laparoscopic and open surgeries. The SORBAFIX™ Absorbable Fixation System is pre-loaded with either 15 or 30 absorbable fasteners that are deployed via a 5mm, low-profile delivery system.